Janelle Hill
Psychiatric/Mental Health · Omaha, NENPI 1801341987
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,930 of the $24,243 with a category attached, or 65.7%. Johnson & Johnson accounts for 80.7% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $20,338, more than ten times the $67 reported in 2021. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $80.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$20K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$564
- Otsuka America Pharmaceutical, Inc.$493
- Alkermes, Inc.$393
- Axsome Therapeutics, Inc.$355
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$15,93066%
- Travel & lodging$2,48810%
- Food & beverage$5,77924%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $19,558 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,020 |
| AbbVie | 35 | $564 |
| Otsuka America Pharmaceutical, Inc. | 24 | $493 |
| Alkermes, Inc. | 20 | $393 |
| Axsome Therapeutics, Inc. | 21 | $355 |
| Noven Therapeutics, LLC | 12 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $272 |
| Lundbeck LLC | 12 | $256 |
| Vanda Pharmaceuticals Inc. | 9 | $179 |
| Janssen Scientific Affairs, LLC | 1 | $140 |
| Neos Therapeutics, LP | 8 | $136 |
| Corium, LLC | 11 | $123 |
| Idorsia Pharmaceuticals US Inc | 7 | $111 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Collegium Pharmaceutical, Inc. | 4 | $61 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Almatica Pharma LLC | 3 | $45 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$19,133
- LYBALVI$424
- INVEGA TRINZA$140
- ABILIFY MAINTENA$130
- Xelstrym$121
- VRAYLAR$120
How this compares
$24,243 in reported general payments places this provider in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 21 | $725 |
| Duloxetine Hcl | 13 | $512 |
| Trazodone Hcl | 17 | $445 |
| Alprazolam | 21 | $278 |
| Lamotrigine | 12 | $122 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Omaha
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.